NEFL and myeloid sarcoma: Several phase 3 trials and population-based studies suggest that serum or CSF concentration of serum NfL (neurofilament light) may be a promising predictor of subsequent relapse rate, worsening of disability, MRI lesion activity, and brain volume loss in all forms of MS, including CIS.